A transatlantic initiative devoted to underwriting new antibiotics and other treatments to tackle drug-resistant infections in developing countries received a big boost Tuesday when the Bill and Melinda Gates Foundation and the U.K. government agreed to fund the effort.
The CARB-X project, which was created two years ago and later secured $455 million in funding from the U.S. government and a public-private partnership in the U.K., is now slated to receive an additional $52 million that will also be invested in getting new treatments into humans in clinical trials.
About the Author Reprints
